Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Douglas James Gazarian, Ph.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gazarian D, Addis ME, Jampel JD, Hoffman E. Contexts of Concealment: Initial Validation of Three Disclosure Avoidance Process Measures. J Pers Assess. 2022 Jul 05; 1-17. PMID: 35787067.
    Citations:    Fields:    
  2. Zimmerman M, Gazarian D, Multach M, Attiullah N, Benoff T, Boerescu DA, Friedman MA, Mehring LB, Moon S, Patel S, Holst CG. A clinically useful self-report measure of psychiatric patients' satisfaction with the initial evaluation. Psychiatry Res. 2017 06; 252:38-44. PMID: 28242516.
    Citations: 6     Fields:    Translation:Humans
  3. Zimmerman M, Holst CG, Clark HL, Multach M, Walsh E, Rosenstein LK, Gazarian D. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years. CNS Drugs. 2016 12; 30(12):1209-1218. PMID: 27541608.
    Citations: 4     Fields:    Translation:Humans
  4. Zimmerman M, Multach MD, Clark HL, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in late life depression antidepressant efficacy trials. Int J Geriatr Psychiatry. 2017 09; 32(9):1009-1016. PMID: 27546477.
    Citations: 1     Fields:    Translation:Humans
  5. Gazarian D, Multach MD, Ellison WD, Chelminski I, Dalrymple K, Zimmerman M. Does 'fear of dying' indicate a more severe presentation of panic disorder? J Anxiety Disord. 2016 05; 40:52-7. PMID: 27105467.
    Citations:    Fields:    Translation:Humans
  6. Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Symptom Severity and the Generalizability of Antidepressant Efficacy Trials: Changes During the Past 20 Years. J Clin Psychopharmacol. 2016 Apr; 36(2):153-6. PMID: 26848791.
    Citations: 1     Fields:    Translation:Humans
  7. Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Variability in the substance use disorder exclusion criterion in antidepressant efficacy trials. J Affect Disord. 2016 07 01; 198:39-42. PMID: 27002283.
    Citations: 1     Fields:    Translation:Humans
  8. Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs. 2016 Mar; 30(3):185-91. PMID: 26818632.
    Citations: 3     Fields:    Translation:Humans
  9. Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord. 2016 Jan 15; 190:357-361. PMID: 26546771.
    Citations: 1     Fields:    Translation:Humans
  10. Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Have Treatment Studies of Depression Become Even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published During the Past 20 Years. Mayo Clin Proc. 2015 Sep; 90(9):1180-6. PMID: 26276679.
    Citations: 17     Fields:    Translation:Humans
  11. Zimmerman M, Gazarian D. Is research on borderline personality disorder underfunded by the National Institute of Health? Psychiatry Res. 2014 Dec 30; 220(3):941-4. PMID: 25446463.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gazarian's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (46)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.